留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

器官移植受者巨细胞病毒感染临床诊疗规范(2019版)

中华医学会器官移植学分会

中华医学会器官移植学分会. 器官移植受者巨细胞病毒感染临床诊疗规范(2019版)[J]. 器官移植, 2019, 10(2): 142-148. doi: 10.3969/j.issn.1674-7445.2019.02.005
引用本文: 中华医学会器官移植学分会. 器官移植受者巨细胞病毒感染临床诊疗规范(2019版)[J]. 器官移植, 2019, 10(2): 142-148. doi: 10.3969/j.issn.1674-7445.2019.02.005

器官移植受者巨细胞病毒感染临床诊疗规范(2019版)

doi: 10.3969/j.issn.1674-7445.2019.02.005
基金项目: 

国家自然科学基金 81570680

国家自然科学基金 81571555

详细信息
    通讯作者:

    石炳毅,Email:shibingyi666@126.com

  • 中图分类号: R617, R373

  • 摘要: 为了进一步规范中国实体器官移植(SOT)受者巨细胞病毒(CMV)感染的诊断和治疗,中华医学会器官移植学分会组织器官移植专家、感染病学专家及呼吸内科专家,在《实体器官移植受者巨细胞病毒感染诊疗指南(2017版)》的基础上,从CMV感染的主要危险因素、实验室诊断、临床类型、预防方案,CMV病的治疗,儿童SOT术后CMV感染或CMV病的防治,CMV肺炎合并伊氏肺孢子菌肺炎的防治等方面,制订本规范,以期为我国SOT术后CMV感染的规范化防治提供指导意见。

     

  • 图  1  CMV肺炎的影像学表现

    Figure  1.  The imaging appearance of CMV pneumonia

    图  2  抢先治疗的推荐流程

    Figure  2.  Recommended procedure for pre-emptive treatment

    图  3  更昔洛韦耐药患者的监测和治疗推荐流程

    GCV为更昔洛韦;VGCV为缬更昔洛韦;FOS为膦甲酸钠;CDV为西多福韦;EC50为半数有效浓度;全剂量GCV为5 mg/kg,高剂量GCV为10 mg/kg,静脉滴注,每日2次(根据肾功能调整剂量)

    Figure  3.  Monitoring and recommended treatment process for ganciclovir resistant patients

  • [1] LINARES L, SANCLEMENTE G, CERVERA C, et al. Influence of cytomegalovirus disease in outcome of solid organ transplant patients[J]. Transplant Proc, 2011, 43(6):2145-2148. DOI: 10.1016/j.transproceed.2011.05.007.
    [2] CANNON MJ, SCHMID DS, HYDE TB. Review of cytomegalovirus seroprevalence and demographic characteristics associated with infection[J]. Rev Med Virol, 2010, 20(4):202-213. DOI: 10.1002/rmv.655.
    [3] RAZONABLE R. Direct and indirect effects of cytomegalovirus: can we prevent them?[J]. Enferm Infecc Microbiol Clin, 2010, 28(1):1-5. DOI: 10.1016/j.eimc.2009.07.008.
    [4] WALKER RC, MARSHALL WF, STRICKLER JG, et al. Pretransplantation assessment of the risk of lymphoproliferative disorder[J]. Clin Infect Dis, 1995, 20(5):1346-1353. doi: 10.1093/clinids/20.5.1346
    [5] GEORGE MJ, SNYDMAN DR, WERNER BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland[J]. Am J Med, 1997, 103(2):106-113. doi: 10.1016/S0002-9343(97)80021-6
    [6] HELANTERÄ I, LAUTENSCHLAGER I, KOSKINEN P. The risk of cytomegalovirus recurrence after kidney transplantation[J]. Transpl Int, 2011, 24(12):1170-1178. DOI: 10.1111/j.1432-2277.2011.01321.x.
    [7] HUMAR A, SNYDMAN D, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplant recipients[J]. Am J Transplant, 2009, 9(Suppl 4): S78-S86. DOI: 10.1111/j.1600-6143.2009.02897.x.
    [8] RAZONABLE RR, HUMAR A, AST Infectious Diseases Community of Practice. Cytomegalovirus in solid organ transplantation[J]. Am J Transplant, 2013,13(Suppl 4):93-106. DOI: 10.1111/ajt.12103.
    [9] DORON S, RUTHAZER R, WERNER BG, et al.Hypogammaglobulinemia in liver transplant recipients: incidence, timing, risk factors, and outcomes[J]. Transplantation,2006, 81(5):697-703. doi: 10.1097/01.tp.0000180531.66518.9e
    [10] KOTTON CN, KUMAR D, CALIENDO AM, et al. The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation[J]. Transplantation, 2018, 102(6):900-931. DOI: 10.1097/TP.0000000000002191.
    [11] GOLDFARB NS, AVERY RK, GOORMASTIC M, et al. Hypogammaglobulinemia in lung transplant recipients[J]. Transplantation, 2001, 71(2):242-246. doi: 10.1097/00007890-200101270-00013
    [12] ESHRAGHI H, HEKMAT R. Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients?[J]. Transplant Proc, 2015, 47(4):1136-1139. DOI: 10.1016/j.transproceed.2014.11.066.
    [13] KANTER J, PALLARDÓ L, GAVELA E, et al. Cytomegalovirus infection renal transplant recipients: risk factors and outcome[J]. Transplant Proc, 2009, 41(6):2156-2158. DOI: 10.1016/j.transproceed.2009.06.057.
    [14] FISHMAN JA, GROSSI PA. Donor-derived infection--the challenge for transplant safety[J]. Nat Rev Nephrol, 2014, 10(11):663-672. DOI: 10.1038/nrneph.2014.159.
    [15] RAZONABLE RR, PAYA CV, SMITH TF. Role of the laboratory in diagnosis and management of cytomegalovirus infection in hematopoietic stem cell and solid-organ transplant recipients[J]. J Clin Microbiol, 2002, 40(3):746-752. doi: 10.1128/JCM.40.3.746-752.2002
    [16] BEAM E, RAZONABLE RR. Cytomegalovirus in solid organ transplantation: epidemiology, prevention, and treatment[J]. Curr Infect Dis Rep, 2012, 14(6):633-641. DOI: 10.1007/s11908-012-0292-2.
    [17] STRIPPOLI GF, HODSON EM, JONES C, et al. Preemptive treatment for cytomegalovirus viremia to prevent cytomegalovirus disease in solid organ transplant recipients[J]. Transplantation, 2006, 81(2):139-145. doi: 10.1097/01.tp.0000183970.71366.da
    [18] EID AJ, RAZONABLE RR. New developments in the management of cytomegalovirus infection after solid organ transplantation[J]. Drugs, 2010, 70(8):965-981. DOI: 10.2165/10898540-000000000-00000.
    [19] HIBBERD PL, TOLKOFF-RUBIN NE, CONTI D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. a randomized controlled trial[J]. Ann Intern Med, 1995, 123(1):18-26. doi: 10.7326/0003-4819-123-1-199507010-00002
    [20] JAMAL AJ, HUSAIN S, LI Y, et al. Risk factors for late-onset cytomegalovirus infection or disease in kidney transplant recipients[J]. Transplantation, 2014, 97(5):569-575. DOI: 10.1097/01.tp.0000438197.38413.f2.
    [21] ASBERG A, HUMAR A, ROLLAG H, et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients[J]. Am J Transplant, 2007, 7(9):2106-2113. doi: 10.1111/ajt.2007.7.issue-9
    [22] TORRE-CISNEROS J, AGUADO JM, CASTON JJ, et al. Management of cytomegalovirus infection in solid organ transplant recipients: SET/GESITRA-SEIMC/REIPI recommendations[J]. Transplant Rev (Orlando), 2016, 30(3):119-143. DOI: 10.1016/j.trre.2016.04.001.
    [23] BHORADE SM, LURAIN NS, JORDAN A, et al. Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients[J]. J Heart Lung Transplant, 2002, 21(12):1274-1282. doi: 10.1016/S1053-2498(02)00463-1
    [24] LURAIN NS, CHOU S. Antiviral drug resistance of human cytomegalovirus[J]. Clin Microbiol Rev, 2010, 23(4):689-712. DOI: 10.1128/CMR.00009-10.
    [25] GREEN M, MICHAELS MG, KATZ BZ, et al. CMV-IVIG for prevention of Epstein Barr virus disease and posttransplant lymphoproliferative disease in pediatric liver transplant recipients[J]. Am J Transplant, 2006, 6(8):1906-1912. doi: 10.1111/ajt.2006.6.issue-8
    [26] KELLY DA, BUCUVALAS JC, ALONSO EM, et al. Long-term medical management of the pediatric patient after liver transplantation: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation[J]. Liver Transpl, 2013, 19(8):798-825. DOI: 10.1002/lt.23697.
    [27] KIZILARSLANOGLU MC, AKSOY S, YILDIRIM NO, et al. Temozolomide-related infections: review of the literature[J]. J BUON, 2011, 16(3):547-550. http://cn.bing.com/academic/profile?id=ebafc8f55b31f53d7360e0ac4190dc29&encoded=0&v=paper_preview&mkt=zh-cn
  • 加载中
图(3)
计量
  • 文章访问数:  244
  • HTML全文浏览量:  153
  • PDF下载量:  36
  • 被引次数: 0
出版历程
  • 收稿日期:  2018-12-26
  • 网络出版日期:  2021-01-19
  • 刊出日期:  2019-03-15

目录

    /

    返回文章
    返回